Tianci International, Inc. 8-K

What Happened
Tianci International, Inc. (CIIT) announced it received a Nasdaq deficiency letter on October 29, 2025, because its closing bid price had been below the $1.00 minimum for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). Nasdaq gave Tianci a 180-calendar-day cure period through April 27, 2026. On April 6, 2026, Nasdaq’s Listing Qualifications Staff informed Tianci that its common stock had regained compliance with the minimum bid price requirement and the matter is now closed.

Key Details

• Nasdaq deficiency letter dated October 29, 2025 cited bid price below $1.00 for 30 consecutive business days.
• Cure period provided: 180 calendar days, deadline April 27, 2026.
• Nasdaq notified Tianci on April 6, 2026 that the company had regained compliance and the issue is closed.
• Relevant rule: Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price requirement).

Why It Matters
Regaining compliance removes the immediate risk of delisting related to the bid-price standard and preserves Tianci’s continued listing on The Nasdaq Capital Market. For investors, this reduces a regulatory overhang that can affect liquidity and investor confidence; no further Nasdaq action on this deficiency is reported in the filing.